ArticleAmerican journal of translational research2023
Serum C reactive protein and procalcitonin are valuable predictors of coronary heart disease and poor prognosis in the elderly.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 citations in OpenAlex.
- Pentraxin 3 is an inflammation-related biomarker that distinguishes early-stage from mid-advanced cardiovascular-kidney-metabolic syndrome.Molecular and cellular biochemistry · 2026Article
- Procalcitonin in acute and chronic coronary syndromes: Diagnostic biomarker of coronary inflammation.Biomolecules & biomedicine · 2025Article
- The Role of C-Reactive Protein in Acute Myocardial Infarction: Unmasking Diagnostic, Prognostic, and Therapeutic Insights.Journal of clinical medicine · 2025Review
- Association between inflammatory burden index and prognosis in patients with coronary heart disease: A retrospective study.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the potential of serum C-reactive protein (CRP) and procalcitonin (PCT) for predicting coronary heart disease (CHD) in elderly patients, as well as their impact on prognosis.
methodsThis retrospective analysis included 120 elderly patients with CHD (CHD group) and 100 patients without cardiovascular disease (control group). CHD patients were followed up for 12 months after discharge. Patients with readmission due to adverse cardiovascular events were incorporated into a poor prognosis group, and the rest were considered a good prognosis group. Serum CRP and PCT were measured by Latex immunoturbidimetric assay and enzyme-linked fluorescent assay.
resultsSerum CRP and PCT levels in the CHD group were considerably higher than those in the control group. Serum CRP and PCT were found to be predictive factors for CHD by logistic regression study, and the area under the curve (AUC) of the combination examination of CRP and PCT was greater than that of CRP or PCT alone, suggesting that the combination was most valuable for the prediction of CHD in the elderly. Furthermore, the levels of CRP and PCT in the poor prognosis group were substantially higher than those in the good prognosis group. Logistic regression found that serum CRP and PCT were independent factors affecting the prognosis of CHD. The AUR of the combined examination of CRP and PCT was greater than that of the CRP or PCT alone, suggesting that the combination had a better prognostic value.
conclusionsSerum PCT and CRP levels are abnormally elevated in elderly patients with CHD, and higher levels of PCT and CRP are associated with higher risk of CHD and poor prognosis. The determination of PCT and CRP is of great significance in guiding clinical treatment.
Indexed as
Identifiers
37434846PMC10331649W4383998055What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.